Non-small cell lung carcinoma (NSLC) is one of the subtypes of lung cancer. Mutation in epidermal growth factor receptor (EGFR) is commonly found in NSLC patients, specifically in lung adenocarcinoma. Therefore, EGFR inhibitors may be used as an effective first line of chemotherapy to treat NSCLC. Two classes of EGFR inhibitor are available: Monoclonal antibodies against extracellular domain of EGFR and small molecule tyrosine kinase inhibitors (TKI) that target kinase domain of EGFR. Due to strong correlation between EGFR mutations and positive TKIs response, EGFR mutational profiling potentially guides to appropriate therapeutic regimens. While most of the countries had established their own prevalence rate for EGFR mutation, until date there is no report on prevalence of EGFR mutation in NSCLC population in Nepal. Therefore, we propose to study EGFR mutation in lung cancer patients visiting Nepal Cancer Hospital and research center (NCHRC), Kathmandu, Nepal. PCR based sequence analysis for both the exonic and intronic EGFR regions that are commonly mutated in NSCLC will be performed on DNA extracted from lung tissues obtained from NSLC patients. This study will also help to some extent in maintenance of nationwide mutational catalogue of lung cancer patients in Nepal.
This project is in technical collaboration with Institute of South Asian Studies, South Asian University and Nepal Cancer Hospital and research Center, Kathmandu.
The project is funded by South Asian University.
COPYRIGHTS © 2016 Centre for Health and Disease Studies-Nepal (CHDS). ALL RIGHTS RESERVED.
Developed & Powered by Eknotech